

AMENDMENTS TO THE CLAIMS

1-40. (Canceled).

41. (Currently Amended) A method for detecting a virus that is not a plus-strand RNA virus in a sample, comprising:

- a) providing:
 - i) a sample;
 - ii) cells susceptible to said virus that is not a plus-strand RNA virus, wherein said not a plus-strand virus is selected from the group consisting of influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, and metapneumovirus; and
 - iii) at least one protease inhibitor;
- b) contacting said cells and said sample in the presence of said protease inhibitor to produce contacted cells, wherein replication of said virus that is not a plus-strand RNA virus in said contacted cells is not reduced relative to replication [[of]] of a coronavirus virus in said cells contacted with said protease inhibitor, wherein said coronavirus replication is at least 25% lower than said not a plus-strand RNA virus replication.

42. (Canceled)

43. (Previously Presented) The method of Claim 41, wherein said influenza virus is chosen from influenza A, influenza B, and influenza C.

44. (Withdrawn) The method of Claim 41, wherein said parainfluenza virus is chosen from parainfluenza 1, parainfluenza 2, parainfluenza 3, and parainfluenza 4.

45. (Withdrawn) The method of Claim 41, wherein said adenovirus is chosen from adenovirus 2, adenovirus 3, adenovirus 4, adenovirus 5, adenovirus 7, adenovirus 9, adenovirus 12, adenovirus 17, and adenovirus 40.

46. (Canceled)

47. (Previously Presented) The method of Claim 41, wherein said coronavirus comprises SARS-coronavirus.

48-51. (Canceled)

52. (Previously Presented) The method of Claim 41, wherein said protease inhibitor is contained in a composition comprising a cyclodextrin.

53. (Previously Presented) The method of Claim 52, wherein said cyclodextrin comprises sulfobutyl ether beta-cyclodextrin sodium.

54. (Previously Presented) The method of Claim 41, wherein said protease inhibitor is selected from Actinonin, Glycyrrhizin, and E64D.

55-68. (Canceled)